These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

397 related items for PubMed ID: 11092281

  • 1. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.
    Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL.
    Diabetes Care; 2000 Nov; 23(11):1605-11. PubMed ID: 11092281
    [Abstract] [Full Text] [Related]

  • 2. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group.
    Einhorn D, Rendell M, Rosenzweig J, Egan JW, Mathisen AL, Schneider RL.
    Clin Ther; 2000 Dec; 22(12):1395-409. PubMed ID: 11192132
    [Abstract] [Full Text] [Related]

  • 3. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus.
    Rosenblatt S, Miskin B, Glazer NB, Prince MJ, Robertson KE, Pioglitazone 026 Study Group.
    Coron Artery Dis; 2001 Aug; 12(5):413-23. PubMed ID: 11491207
    [Abstract] [Full Text] [Related]

  • 4. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study.
    Kipnes MS, Krosnick A, Rendell MS, Egan JW, Mathisen AL, Schneider RL.
    Am J Med; 2001 Jul; 111(1):10-7. PubMed ID: 11448655
    [Abstract] [Full Text] [Related]

  • 5. Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled study. The Troglitazone Study Group.
    Fonseca VA, Valiquett TR, Huang SM, Ghazzi MN, Whitcomb RW.
    J Clin Endocrinol Metab; 1998 Sep; 83(9):3169-76. PubMed ID: 9745421
    [Abstract] [Full Text] [Related]

  • 6. Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials. The Glipizide Gastrointestinal Therapeutic System Study Group.
    Simonson DC, Kourides IA, Feinglos M, Shamoon H, Fischette CT.
    Diabetes Care; 1997 Apr; 20(4):597-606. PubMed ID: 9096986
    [Abstract] [Full Text] [Related]

  • 7. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone.
    Miyazaki Y, Mahankali A, Matsuda M, Glass L, Mahankali S, Ferrannini E, Cusi K, Mandarino LJ, DeFronzo RA.
    Diabetes Care; 2001 Apr; 24(4):710-9. PubMed ID: 11315836
    [Abstract] [Full Text] [Related]

  • 8. A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus.
    Herz M, Johns D, Reviriego J, Grossman LD, Godin C, Duran S, Hawkins F, Lochnan H, Escobar-Jiménez F, Hardin PA, Konkoy CS, Tan MH.
    Clin Ther; 2003 Apr; 25(4):1074-95. PubMed ID: 12809958
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy.
    Rosenstock J, Einhorn D, Hershon K, Glazer NB, Yu S, Pioglitazone 014 Study Group.
    Int J Clin Pract; 2002 May; 56(4):251-7. PubMed ID: 12074206
    [Abstract] [Full Text] [Related]

  • 10. Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study.
    Patel J, Anderson RJ, Rappaport EB.
    Diabetes Obes Metab; 1999 May; 1(3):165-72. PubMed ID: 11220295
    [Abstract] [Full Text] [Related]

  • 11. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes.
    Phillips LS, Grunberger G, Miller E, Patwardhan R, Rappaport EB, Salzman A, Rosiglitazone Clinical Trials Study Group.
    Diabetes Care; 2001 Feb; 24(2):308-15. PubMed ID: 11213884
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of initial combination therapy with sitagliptin and pioglitazone in patients with type 2 diabetes: a 54-week study.
    Yoon KH, Steinberg H, Teng R, Golm GT, Lee M, O'Neill EA, Kaufman KD, Goldstein BJ.
    Diabetes Obes Metab; 2012 Aug; 14(8):745-52. PubMed ID: 22405352
    [Abstract] [Full Text] [Related]

  • 13. Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes.
    Miyazaki Y, Matsuda M, DeFronzo RA.
    Diabetes Care; 2002 Mar; 25(3):517-23. PubMed ID: 11874940
    [Abstract] [Full Text] [Related]

  • 14. Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.
    Derosa G, Cicero AF, D'Angelo A, Gaddi A, Ciccarelli L, Piccinni MN, Salvadeo SA, Pricolo F, Ferrari I, Gravina A, Ragonesi PD.
    Clin Ther; 2006 May; 28(5):679-88. PubMed ID: 16861090
    [Abstract] [Full Text] [Related]

  • 15. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial.
    Derosa G, Cicero AF, Gaddi A, Ragonesi PD, Fogari E, Bertone G, Ciccarelli L, Piccinni MN.
    Clin Ther; 2004 May; 26(5):744-54. PubMed ID: 15220018
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of alogliptin in patients with type 2 diabetes mellitus: A multicentre randomized double-blind placebo-controlled Phase 3 study in mainland China, Taiwan, and Hong Kong.
    Pan C, Han P, Ji Q, Li C, Lu J, Yang J, Li W, Zeng J, Hsieh AT, Chan J.
    J Diabetes; 2017 Apr; 9(4):386-395. PubMed ID: 27171508
    [Abstract] [Full Text] [Related]

  • 17. Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Roberts VL, Stewart J, Issa M, Lake B, Melis R.
    Clin Ther; 2005 Oct; 27(10):1535-47. PubMed ID: 16330290
    [Abstract] [Full Text] [Related]

  • 18. [The efficacy and safety of pioglitazone hydrochloride in combination with sulphonylureas and metfomin in the treatment of type 2 diabetes mellitus a 12-week randomized multi-centres placebo-controlled parallel study].
    Pan C, Gao Y, Gao X, Li G, Luo B, Shi H, Tian H, Jia P, Lin H, Xing X, Zhao Y, Zhou L.
    Zhonghua Nei Ke Za Zhi; 2002 Jun; 41(6):388-92. PubMed ID: 12137601
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.
    Pratley RE, Reusch JE, Fleck PR, Wilson CA, Mekki Q, Alogliptin Study 009 Group.
    Curr Med Res Opin; 2009 Oct; 25(10):2361-71. PubMed ID: 19650752
    [Abstract] [Full Text] [Related]

  • 20. Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic subjects: a 12-week, double-blind, placebo-controlled dose-ranging study with an open pioglitazone arm.
    Saad MF, Greco S, Osei K, Lewin AJ, Edwards C, Nunez M, Reinhardt RR, Ragaglitazar Dose-Ranging Study Group.
    Diabetes Care; 2004 Jun; 27(6):1324-9. PubMed ID: 15161783
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.